Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Parkinson disease: interrogations and solutions]

H Allain1, D Bentué-Ferrer

  • 1Laboratoire de Pharmacologie expérimentale et clinique, Faculté de Médecine, Rennes. Herve.Allain@univ-rennes1.fr

Presse Medicale (Paris, France : 1983)
|June 7, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A double-blind, placebo-controlled, enriched population study of tacrine in patients with Alzheimer's disease.

European journal of neurology·2013
Same author

Assessment of interindividual variability of plasma concentrations after administrazion of high doses of intravenous amoxicillin or cloxacillin in critically ill patients.

Journal of chemotherapy (Florence, Italy)·2011
Same author

Evaluating patient satisfaction with specific migraine therapy based on initial treatment expectations: the PAX study.

Current medical research and opinion·2009
Same author

Comparative study of the effects of zopiclone (7.5 mg), zolpidem, flunitrazepam and a placebo on nocturnal cognitive performance in healthy subjects, in relation to pharmacokinetics.

European psychiatry : the journal of the Association of European Psychiatrists·2009
Same author

Gradual withdrawal of zopiclone (7.5 mg) and zolpidem (10 mg) in insomniacs treated for at least 3 months.

European psychiatry : the journal of the Association of European Psychiatrists·2009
Same author

General safety profile of zolpidem: safety in elderly, overdose and rebound effects.

European psychiatry : the journal of the Association of European Psychiatrists·2009
Same journal

Predictive analytics and risk stratification models in internal medicine: from risk scores to real-time machine learning.

Presse medicale (Paris, France : 1983)·2026
Same journal

Artificial Intelligence in skin disease therapeutics: from drug discovery to personalized treatment pathways.

Presse medicale (Paris, France : 1983)·2026
Same journal

AI in clinical diagnostics in dermatology: applications, validation, and real-world use cases.

Presse medicale (Paris, France : 1983)·2026
Same journal

Artificial Intelligence in medical research and publishing: progress, risks, and future perspectives.

Presse medicale (Paris, France : 1983)·2026
Same journal

Ethical, legal, and regulatory challenges in AI-based healthcare tools.

Presse medicale (Paris, France : 1983)·2026
Same journal

Decision-making for clinicians.

Presse medicale (Paris, France : 1983)·2026
See all related articles

Idiopathic Parkinson's disease involves the loss of specific brain cells. Current treatments aim for long-term benefits and reduced motor complications using medications and exploring new therapies.

Area of Science:

  • Neurodegenerative diseases
  • Neurobiology of central nervous system dopaminergic pathways

Context:

  • Idiopathic Parkinson's disease (IPD) is characterized by the selective destruction of dopaminergic neurons in the substantia nigra pars compacta.
  • Since its initial description in 1817, understanding IPD has advanced, driven by neurobiological insights into dopaminergic pathways.

Purpose:

  • To discuss current therapeutic goals in managing Parkinson's disease, focusing on achieving sustained benefits while mitigating motor complications.
  • To explore emerging therapeutic avenues and the critical role of clinical trials in advancing Parkinson's disease treatment.

Summary:

  • Current Parkinson's disease management strategies focus on long-term efficacy and minimizing motor complications like fluctuations, dystonias, and dyskinesias.
  • Achieving these therapeutic goals involves utilizing low doses of levodopa, dopaminergic agonists, and monoamine-oxidase-B inhibitors.

Related Experiment Videos

Impact:

  • Future advancements in Parkinson's disease treatment may include catechol-O-methyl transferase inhibitors, thalamic stimulation, and fetal grafts.
  • The primary challenge lies in developing compounds that can antagonize neuronal cell death, underscoring the need for high-quality clinical trials to guide therapeutic approaches.